interferon alpha inα therapy despite good efficacy cure hc infect lead major side effect particular induce strong periphery cell lymphocytopenia analyze early consent thymic function homeostasis patient act chronic phase hcvinfect well hivhcv connect revolt subset est flow cytometri measure quantify receptor excise circle tree est intrathym precursor provider first four month follow init begin month profound observe include naïv cell recent migr rte assoc inhibit interleukin il plasma content rapidly drop progress neither consent higher consumer cytokine due neutral soluble cd decrease correct decline viral load active blood data demons inαbas impact thymopoiesi consent aperture effect might detriment continue may lead increase level infect risk altogether studi suggest therapeutic potent painter inαtreat 